Predicting synergism of cancer drug combinations using NCI-ALMANAC data
Pavel SidoroviD, Stefan NaulaertsiD, Jérémy Ariey-BonnetiD, Eddy PasquieriD, Pedro J. BallesteriD
Abstract
BackgroundDrug combinations are of great interest for cancer treatment. Unfortunately, the discovery of synergistic combinations by purely experimental means is only feasible on small sets of drugs. In silico modeling methods can substantially widen this search by providing tools able to predict which of all possible combinations in a large compound library are synergistic. Here we investigate to which extent drug combination synergy can be predicted by exploiting the largest available dataset to date (NCI-ALMANAC, with over 290,000 synergy determinations).\n\nMethodsEach cell line is modeled using primarily two machine learning techniques, Random Forest (RF) and Extreme Gradient Boosting (XGBoost), on the datasets provided by NCI-ALMANAC. This large-scale predictive modeling study comprises more than 5000 pair-wise drug combinations, 60 cell lines, 4 types of models and 5 types of chemical features. The application of a powerful, yet uncommonly used, RF-specific technique for reliability prediction is also investigated.\n\nResultsThe evaluation of these models shows that it is possible to predict the synergy of unseen drug combinations with high accuracy (Pearson correlations between 0.43 and 0.86 depending on the considered cell line, with XGBoost providing slightly better predictions than RF). We have also found that restricting to the most reliable synergy predictions results in at least two-fold error decrease with respect to employing the best learning algorithm without any reliability estimation. Alkylating agents, tyrosine kinase inhibitors and topoisomerase inhibitors are the drugs whose synergy with other partner drugs are better predicted by the models.\n\nConclusionsDespite its leading size, NCI-ALMANAC comprises an extremely small part of all conceivable combinations. Given their accuracy and reliability estimation, the developed models should drastically reduce the number of required in vitro tests by predicting in silico which of the considered combinations are likely to be synergistic.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 152
- FWCI
- 10.89
- Field percentile
- top 1%
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multi-task learning predicts drug combination synergy in cells and in the clinic
C. M. Gilvary, J. R. Dry, O. Elemento·bioRxiv·Mar 13, 2019
- A systematic evaluation of deep learning methods for the prediction of drug synergy in cancer
Delora Baptista, Pedro Gabriel Ferreira, Miguel Rocha·PLoS Computational BiologyPeer-reviewed·Mar 23, 2023
- ACDA: Implementation of an Augmented Drug Synergy Prediction Algorithm
Sergii Domanskyi, Emily L. Jocoy, … Carol J. Bult·Bioinformatics AdvancesPeer-reviewed·Jan 1, 2023
- Predicting the effects of drug combinations using probabilistic matrix factorization
Ron Nafshi, Timothy R. Lezon·Frontiers in BioinformaticsPeer-reviewed·Aug 13, 2021
- Logical modeling: Combining manual curation and automated parameterization to predict drug synergies
Åsmund Flobak, John Zobolas, … Martin T. R. Kuiper·bioRxiv·Jun 28, 2021
- Explainable machine learning prediction of synergistic drug combinations for precision cancer medicine
Joseph D. Janizek, Safiye Celik, Su-In Lee·bioRxiv·May 27, 2018